Urology News and Research

Latest Urology News and Research

U of Alberta researchers win Canadian Society of Chemistry award

A one-of-a-kind Canadian research group, based in the Faculty of Medicine & Dentistry at the University of Alberta, has now won every award handed out by the Canadian Society of Chemistry for analytical and environmental chemistry.

4 Jun 2011

Patent infringement suit filed against Impax Laboratories in connection with Detrol

Impax Laboratories, Inc. today confirms that Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol (tolterodine tartrate) immediate-release, 1 mg and 2 mg tablets.

4 Jun 2011

Mount Sinai to participate in Medtronic CoreValve U.S. Clinical Trial

Mount Sinai Medical Center in Miami Beach, Florida announced its participation in the Medtronic CoreValve U.S. Clinical Trial, which will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis. Mount Sinai is now among a select number of leading hospitals across the U.S. to participate in this trial.

From Medtronic 4 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4.

3 Jun 2011

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

3 Jun 2011

U-M study shows decline in surgery mortality for eight different high-risk operations

Surgery death rates have dropped nationwide over the past decade, according to a University of Michigan Health System study that reveals cancer surgeries have seen the most dramatic improvement in safety.

3 Jun 2011

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).

1 Jun 2011

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

UK's NICE issues guidance on PTNS treatment for faecal incontinence

Uroplasty, Inc., announced today that the United Kingdom's National Institute for Health and Clinical Excellence issued guidance on percutaneous tibial nerve stimulation for the treatment of faecal incontinence.

31 May 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

Canadian women know more about ovarian cancer than they did six years ago, but misconceptions remain that could lead to late diagnosis of the country's most fatal gynecologic cancer - a disease that claims the lives of 70% of those diagnosed.

30 May 2011

NovaShunt launches new corporate identity and product branding

NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG it prepares for the upcoming launch of the ALFApump System in Europe.

30 May 2011

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

The U.S. Food and Drug Administration today approved a sterile, injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change, fiber therapy or anti-motility medications failed.

30 May 2011

Hysterectomy procedures will continue to decline due to advantages of less-invasive alternatives: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, hysterectomy procedures as a treatment for menorrhagia and uterine fibroids will continue to decline at a rate of three percent a year through 2015. This decline is due to the growing advantages of less-invasive alternatives, primarily global endometrial ablation (GEA), and uterine artery embolization (UAE).

27 May 2011

Studies find antibiotics overused for children with asthma, urinary tract infections

Two new studies led by researchers at the University of California, San Francisco have found some antibiotics may be overused for children with asthma and urinary tract infections.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Watson announces acquisition of Specifar Pharmaceuticals

Watson Pharmaceuticals, Inc. and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million in cash and certain contingent consideration.

25 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

Nerve stimulation device approved for pain

The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.

From Medtronic 24 May 2011